Osborne Clarke has provided legal advice to SwissHealth Ventures, the venture capital arm of Swiss health insurer CSS, and Belgian investor Capricorn Partners on a EUR 11 million seed financing round in Frankfurt-based healthtech start-up Oska Health. Capricorn Partners and SwissHealth Ventures led the round, which also included BMH, LBBW Venture Capital, Revent, GoHub Ventures and Aurum Impact.
Oska Health, founded in 2022 by Niklas Best, Claudia Ehmke and Dr Malte Waldeck, is developing a hybrid care model for multimorbid, chronically ill patients that combines in-person support by certified health coaches with an AI-supported care platform. The offering is already being implemented with more than 20 statutory health insurers in Germany and aims to close the care gap between doctors’ appointments, improve therapy adherence and reduce avoidable hospital admissions.
The new financing round is intended in particular to facilitate the further expansion of the technological infrastructure, the strengthening of the teams in medicine, product development and care, and the scaling of the existing selective-contract models with statutory health insurers. In the medium term, Oska Health is also examining other European markets that face structurally similar challenges in caring for people with chronic conditions.
Through their commitment, SwissHealth Ventures and Capricorn Partners underline the growing importance of digital care models that demonstrate not only technological innovation but also a viable integration into the existing reimbursement and care structures of healthcare systems. Oska Health’s care model is based on close collaboration with health insurers and medical networks and complements medical treatment pathways with continuous, everyday support.
“The seed funding in Oska Health is a strong signal for data-driven, hybrid care models in the field of chronic diseases. The combination of medical expertise, AI-based infrastructure and real-world tested selective contract models with more than 20 statutory health insurers addresses one of the central structural challenges of modern healthcare systems,” said Maximilian Vocke, Partner at Osborne Clarke. “The investment also demonstrates that international investors are specifically investing in digital health solutions that combine clinical impact with economic scalability.”
Osborne Clarke advised SwissHealth Ventures and Capricorn Partners comprehensively on the corporate, contractual and regulatory aspects of the seed financing round. The advice included, among other things, structuring the investment, negotiating the financing documentation and advising on data protection and the regulatory classification of the business model in Germany’s highly regulated digital health environment.
The Osborne Clarke team that advised SwissHealth Ventures and Capricorn Partners on the seed financing round in Oska Health was led by Maximilian Vocke and Robin Eyben and included Robert Marx, Vanessa Petre Linbenciuc, Anne Müller, Espen Schneider (all Corporate / Transactions), Dr Florian Reiling, Dr Tim Reinhard, Dr Jonas Völkel (all IP), Julia Kaufmann, Dr Florian Eisenmenger (both Data Protection), Tamara Lehmann, Marina Fröhlich (both Commercial), Christoph Seidler, Anna Lehner (both Employment), Lea Hauser (FDI / Merger Control) and Laura Valeske (Legal Project Management).
